IRIS UniCatt

Salutari, Vanda
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.305
EU - Europa 1.233
AS - Asia 875
SA - Sud America 88
AF - Africa 12
OC - Oceania 2
Totale 3.515
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.291
CN - Cina 444
DE - Germania 357
SG - Singapore 221
IT - Italia 214
SE - Svezia 201
IE - Irlanda 89
BR - Brasile 80
IN - India 77
UA - Ucraina 68
FR - Francia 64
PL - Polonia 56
ID - Indonesia 53
RU - Federazione Russa 43
FI - Finlandia 36
GB - Regno Unito 34
KR - Corea 23
TR - Turchia 17
NL - Olanda 14
AT - Austria 13
BE - Belgio 12
HK - Hong Kong 9
CA - Canada 8
JP - Giappone 7
CI - Costa d'Avorio 6
AR - Argentina 5
CH - Svizzera 5
CZ - Repubblica Ceca 5
IR - Iran 4
VN - Vietnam 4
IL - Israele 3
LT - Lituania 3
MX - Messico 3
AW - Aruba 2
BG - Bulgaria 2
KZ - Kazakistan 2
LV - Lettonia 2
MA - Marocco 2
MK - Macedonia 2
NO - Norvegia 2
TJ - Tagikistan 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AM - Armenia 1
AU - Australia 1
AZ - Azerbaigian 1
BD - Bangladesh 1
BZ - Belize 1
CL - Cile 1
DK - Danimarca 1
EG - Egitto 1
GA - Gabon 1
GE - Georgia 1
GR - Grecia 1
HU - Ungheria 1
IM - Isola di Man 1
IQ - Iraq 1
IS - Islanda 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MD - Moldavia 1
MT - Malta 1
NZ - Nuova Zelanda 1
PE - Perù 1
PY - Paraguay 1
RO - Romania 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
ZA - Sudafrica 1
Totale 3.515
Salva come PNG Salva come JPEG
Città #
Chandler 249
Hangzhou 183
Ashburn 134
Singapore 129
Dublin 89
Beijing 63
Hyderabad 56
San Mateo 54
Warsaw 52
Jakarta 51
Wilmington 48
Ann Arbor 46
Jacksonville 43
New York 43
Rome 34
Redmond 33
Nanjing 31
Moscow 26
Boston 25
Bremen 25
Milan 25
Dearborn 24
Cattolica 23
Houston 23
Princeton 21
Hefei 20
Nürnberg 20
Fairfield 19
Los Angeles 19
Helsinki 18
Seoul 18
Munich 16
Redwood City 16
Seattle 15
Marseille 13
Nanchang 13
The Dalles 13
Woodbridge 13
Izmir 12
Lawrence 12
Shenyang 12
Naples 11
Brussels 10
Frankfurt am Main 10
Düsseldorf 9
Washington 9
Boardman 8
Cambridge 8
Hong Kong 8
Jiaxing 8
Vienna 8
Kunming 7
Mountain View 7
University Park 7
Abidjan 6
Bologna 6
Detroit 6
Falkenstein 6
Portsmouth 6
Zhengzhou 6
Albano Laziale 5
Guangzhou 5
Leawood 5
Amsterdam 4
Andover 4
Cosenza 4
Hebei 4
Lauterbourg 4
New Haven 4
Nuremberg 4
Santa Clara 4
Shanghai 4
Asti 3
Busto Arsizio 3
Changsha 3
Dong Ket 3
Guiyang 3
Jeju City 3
Lanzhou 3
London 3
Norwalk 3
Olomouc 3
Ottawa 3
Paris 3
Phoenix 3
Rio de Janeiro 3
Simi Valley 3
Tacoma 3
Tel Aviv 3
Toronto 3
Altamura 2
Augusta 2
Bari 2
Brno 2
Buenos Aires 2
Campinas 2
Caxias do Sul 2
Council Bluffs 2
Dushanbe 2
Fortaleza 2
Totale 2.050
Salva come PNG Salva come JPEG
Nome #
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer 457
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial 316
Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence 265
Paclitaxel, epirubicin, and cisplatin (TEP) regimen as neoadjuvant treatment in locally advanced cervical cancer: long-term results 181
Early detection of recurrence or progression disease in patients with ovarian cancer after primary debulking surgery: a diagnostic challenge still unresolved. Correlation between CT findings and CA 125 levels. 145
Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer. 142
A preliminary Quality Control (QC) for next generation sequencing (NGS) library evaluation turns out to be a very useful tool for a rapid detection of BRCA1/2 deleterious mutations 142
The 'lead vessel': a vascular ultrasound feature of metastasis in the ovaries. 106
Concomitant boost dose escalation plus large-field preoperative chemoradiation in locally advanced carcinoma of the uterine cervix: results of a phase I study (LARA-CC-1). 103
"Occult" ovarian Leydig cell tumor: when laboratory tells more than imaging 101
Stereotactic radiotherapy in recurrent gynecological cancer: a case series 95
Impact of bevacizumab containing first line chemotherapy on recurrent disease in epithelial ovarian cancer: A case-control study 90
Successful multimodal treatment of a breast cancer patient with a recurrence invading the chest wall 89
Optimizing treatment in recurrent epithelial ovarian cancer 77
Neoadjuvant Chemotherapy Followed by Maintenance Therapy With or Without Bevacizumab in Unresectable High-Grade Serous Ovarian Cancer: A Case-Control Study 64
Successful multimodal treatment of a breast cancer patient with a recurrence invading the chest wall 62
New medical approaches in advanced ovarian cancer 59
Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer 58
Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial 57
Controversy in treatment of advanced ovarian cancer 56
Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials 56
Immunotherapy-related imaging findings in patients with gynecological malignancies: What radiologists need to know 56
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial 54
Combining targeted therapies in ovarian cancer 54
Neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel: A phase II, open label multicenter study (NUVOLA trial) 52
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 51
Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study 51
PARP Inhibitors Resistance: Mechanisms and Perspectives 48
Newly diagnosed ovarian cancer: Which first-line treatment? 48
A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer 47
Medi-Cinema: A Pilot Study on Cinematherapy and Cancer as A New Psychological Approach on 30 Gynecological Oncological Patients 47
Recent progress in the use of pharmacotherapy for endometrial cancer 46
Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome 46
A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer 44
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: A retrospective MITO group study 44
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis 43
Advanced and recurrent endometrial cancer: State of the art and future perspectives 43
Medi-Cinema: A Pilot Study on Cinematherapy and Cancer as A New Psychological Approach on 30 Gynecological Oncological Patients 43
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel 42
A retrospective analysis of trabectedin infusion by peripherally inserted central venous catheters: A multicentric Italian experience 41
Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon? 40
Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: The MITO-8,MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study 39
Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinumbased chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer 38
Radical Surgery in Advanced Cervical Cancer Patients Receiving Bevacizumab-Containing Chemotherapy: A "Real Life Experience" 37
Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives 36
Efficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26) 31
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 29
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 27
Genome tumor profiling in endometrial cancer and clinical relevance in endometrial cancer management: A retrospective single-center experience 25
Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) Applied to Platinum-Resistant Recurrence of Ovarian Tumor: A Single-Institution Experience (ID: PARROT Trial) 24
New therapeutic targets for endometrial cancer: a glimpse into the preclinical sphere 22
Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study 11
Real-world outcomes of PARP inhibitor maintenance in advanced ovarian cancer: a focus on disease patterns and treatment modalities at recurrence 9
Totale 3.989
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.654
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.654
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202097 0 0 0 0 0 0 0 0 0 0 49 48
2020/2021383 36 24 5 23 50 32 40 30 22 45 59 17
2021/2022286 39 16 2 15 17 6 3 60 5 13 54 56
2022/2023722 67 98 46 104 58 93 27 50 94 20 41 24
2023/2024511 20 131 29 35 18 82 48 15 4 20 53 56
2024/2025816 28 17 82 39 71 38 40 46 155 135 165 0
Totale 3.989